Related Experiment Video
Updated: Feb 26, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
5.4K
Risk Assessment for Drug-Induced Hyperbilirubinemia: A Mechanistic Approach.
Rajeev Kumar1, Ansu Kumar1, Aftab Alam1
1Cellworks Group, Inc., South San Francisco, California, USA.
CPT: Pharmacometrics & Systems Pharmacology
|February 24, 2026
Summary
This study developed a mechanistic model to predict drug-induced hyperbilirubinemia risk using genetic markers and drug interaction data. The model helps assess patient risk based on genetic variations and drug effects on liver transporters and enzymes.
Area of Science:
- Pharmacology
- Biochemistry
- Computational Biology
Background:
- Hyperbilirubinemia is a key indicator of drug-induced liver injury.
- Understanding drug interactions with bilirubin metabolism pathways is crucial for predicting toxicity.
Purpose of the Study:
- To develop an ordinary differential equation (ODE)-based mechanistic model of human bilirubin metabolism.
- To assess hyperbilirubinemia risk by integrating genetic markers and drug-specific transporter/enzyme interactions.
Main Methods:
- Constructed an ODE model of bilirubin synthesis, transport, conjugation, and elimination.
- Incorporated key enzymes (UGT1A1) and transporters (OATP1B1, MRP2, MRP3).
- Parametrized and validated the model using in vitro, human data, and genetic disease cases.
Main Results:
- Simulated a 90% reduction in OATP1B1 activity increased bilirubin levels (1.58-fold unconjugated, 2.2-fold conjugated).
- Sensitivity analysis showed increased OATP1B1 sensitivity with low UGT1A1 activity.
- Linked nilotinib-induced hyperbilirubinemia to UGT1A1 mutations and assessed risks for other drugs (nelfinavir, atazanavir, TAK-875).
Conclusions:
- The mechanistic model effectively predicts hyperbilirubinemia risk.
- Drug-induced hyperbilirubinemia risk is influenced by drug-protein binding and patient pharmacogenetics (OATP1B1, UGT1A1, MRP2).
- This approach aids in personalized risk assessment for drug-induced liver toxicity.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
298
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
298
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
266
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
266
01:24Drug Toxicity: Risk factors
55
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
55
01:16Drug toxicity: Idiosyncratic Reactions
62
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
62
01:16Drug Biotransformation: Overview
4.0K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
4.0K